SELLAS Life Sciences (SLS) Enterprise Value (2010 - 2026)
SELLAS Life Sciences' (SLS) quarterly Enterprise Value came in at -$107.1 million in Q1 2026, down 107000.0% year-on-year from N/an in Q1 2025, and down 107000.0% on a QoQ basis from -$100000.0 in Q4 2025.
SELLAS Life Sciences (SLS) Enterprise Value (2010 - 2026) Analysis & Trends
SELLAS Life Sciences (SLS) has 17 years of Enterprise Value data on file, last reported at -$107.1 million in Q1 2026.
- On a quarterly basis, Enterprise Value fell 107000.0% year-over-year to -$107.1 million in Q1 2026; TTM through Mar 2026 was -$107.1 million, a 107000.0% decrease from a year earlier, with the FY2025 full-year figure at -$100000.0, up 99.28% from the prior year.
- Enterprise Value for Q1 2026 stood at -$107.1 million, down from -$100000.0 in the prior quarter.
- Over the last five years, Enterprise Value for SLS reached as high as -$100000.0 in Q1 2022 and fell as low as -$107.1 million in Q1 2026.
- Historically, Enterprise Value has averaged -$15.7 million across 5 years, with a median of -$4.0 million in 2023.
- Across the five-year window, Enterprise Value jumped 99.62% in 2022 and tumbled 107000.0% in 2026, its largest moves.
- Year by year, Enterprise Value stood at -$17.1 million in 2022, then jumped by 99.42% to -$100000.0 in 2023, then sank by 13786.0% to -$13.9 million in 2024, then soared by 99.28% to -$100000.0 in 2025, then tumbled by 107000.0% to -$107.1 million in 2026.
- Per Business Quant data, the three most recent Enterprise Value figures were -$107.1 million in Q1 2026, -$100000.0 in Q4 2025, and -$44.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | -61.40 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.83 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | -4.79 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -1.91 Bn |
| 10 | SELLAS Life Sciences | 1.96 Bn | 1.96 Bn | - | -107.10 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -107.10 Mn |
| Dec 31, 2025 | -100,000.00 |
| Sep 30, 2025 | -44.30 Mn |
| Jun 30, 2025 | -25.30 Mn |
| Mar 31, 2025 | -100,000.00 |
| Dec 31, 2024 | -13.89 Mn |
| Sep 30, 2024 | -21.03 Mn |
| Jun 30, 2024 | -9.10 Mn |
| Mar 31, 2024 | -100,000.00 |
| Dec 31, 2023 | -100,000.00 |
| Sep 30, 2023 | -4.00 Mn |
| Jun 30, 2023 | -100,000.00 |
| Mar 31, 2023 | -23.90 Mn |
| Dec 31, 2022 | -17.13 Mn |
| Sep 30, 2022 | -100,000.00 |
| Jun 30, 2022 | -100,000.00 |
| Mar 31, 2022 | -100,000.00 |
| Dec 31, 2021 | -100,000.00 |
| Sep 30, 2021 | -26.28 Mn |
| Jun 30, 2021 | -100,000.00 |